KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $88.1 million.

  • Jazz Pharmaceuticals' Share-based Compensation rose 4746.49% to $88.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $290.5 million, marking a year-over-year increase of 2585.53%. This contributed to the annual value of $248.0 million for FY2024, which is 934.75% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Share-based Compensation stood at $88.1 million, which was up 4746.49% from $64.5 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Share-based Compensation high stood at $88.1 million for Q3 2025, and its period low was $34.5 million during Q1 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' median Share-based Compensation value was $56.7 million (recorded in 2024), while the average stood at $58.2 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Share-based Compensation soared by 7538.21% in 2021, and later plummeted by 1399.82% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Share-based Compensation (Quarter) stood at $53.1 million in 2021, then increased by 15.89% to $61.6 million in 2022, then fell by 14.0% to $52.9 million in 2023, then surged by 32.58% to $70.2 million in 2024, then rose by 25.55% to $88.1 million in 2025.
  • Its last three reported values are $88.1 million in Q3 2025, $64.5 million for Q2 2025, and $67.7 million during Q1 2025.